Hepatic flare after telbivudine withdrawal and efficacy of postpartum antiviral therapy for pregnancies with chronic hepatitis B virus

Journal of Gastroenterology and Hepatology (Australia)

Volumn 32, Issue 1, 2017, Pages 177-183

  Liu, Jinfeng ^a   Wang, Jing ^a   Jin, Dongfang ^b   Qi, Caijing ^a   Yan, TaoTao ^a   Cao, Furong ^a   Jin, Li ^a   Tian, Zhen ^a   Guo, Dandan ^a   Yuan, Ningxia ^c   Feng, Weihong ^d   Zhang, Shulin ^a   Zhao, Yingren ^a   Chen, Tianyan ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b Shaanxi Kangfu Hospital   (China)

^c Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine   (China)

^d SenGong Hospital of Shaanxi   (China)

Author keywords

chronic HBV; extended antiviral therapy; postpartum hepatic flare

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATINE KINASE; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; TELBIVUDINE; VIRUS DNA; ANTIVIRUS AGENT; THYMIDINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; APGAR SCORE; ARTICLE; CHRONIC HEPATITIS B; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HUMAN; IMMUNOPROPHYLAXIS; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEWBORN; OBSTETRIC DELIVERY; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; PUERPERIUM; RASH; REFERENCE VALUE; SEROCONVERSION; THIRD TRIMESTER PREGNANCY; VACCINATION; VERTICAL TRANSMISSION; ANALOGS AND DERIVATIVES; BLOOD; DRUG ADMINISTRATION; HEPATITIS B, CHRONIC; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; TRANSMISSION; VIROLOGY; YOUNG ADULT;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; THYMIDINE; YOUNG ADULT;

EID: 85008467909     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13436     Document Type: Article

References (29)

1. Yang Y, Jin L, He YL et al. Hepatitis B virus infection in clustering of infection in families with unfavorable prognoses in northwest China. J. Med. Virol. 2013; 85: 1893–1899.
2. Wen WH, Chang MH, Zhao LL et al. Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J. Hepatol. 2013; 59: 24–30.
3. Chen T, Wang J, Feng Y et al. Dynamic changes of HBV markers and HBV DNA load in infants born to HBsAg(+) mothers: can positivity of HBsAg or HBV DNA at birth be an indicator for HBV infection of infants? BMC Infect. Dis. 2013; 13: 524.
4. Wiseman E, Fraser MA, Holden S et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med. J. Aust. 2009; 190: 489–492.
5. Xu WM, Cui YT, Wang L et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J. Viral Hepat. 2009; 16: 94–103.
6. Han GR, Cao MK, Zhao W et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J. Hepatol. 2011; 55: 1215–1221.
7. Zhang H, Pan CQ, Pang Q et al. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology 2014; 60: 468–476.
8. Celen MK, Mert D, Ay M et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. World J. Gastroenterol. 2013; 19: 9377.
9. Sarkar M, Terrault NA. Ending vertical transmission of hepatitis B: the third trimester intervention. Hepatology 2014; 60: 448–451.
10. Trowsdale J, Betz AG. Mother's little helpers: mechanisms of maternal-fetal tolerance. Nat. Immunol. 2006; 7: 241–246.
11. Elefsiniotis IS, Tsoumakas K, Kapritsou M et al. Liver function tests in viremic and nonviremic chronic hepatitis B virus-infected pregnant women: importance of alanine aminotransferase/sodium ratio. Gastroenterol. Nurs. 2013; 36: 422–428.
12. Angel Garcia AL. Effect of pregnancy on pre-existing liver disease physiological changes during pregnancy. Ann. Hepatol. 2006; 5: 184–186.
13. Gaunt G, Ramin K. Immunological tolerance of the human fetus. Am. J. Perinatol. 2001; 18: 299–312.
14. Giles M, Visvanathan K, Lewin S et al. Clinical and virological predictors of hepatic flares in pregnant women with chronic hepatitis B. Gut 2014; 64: 1810–1815.
15. Nguyen V, Tan PK, Greenup AJ et al. Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare. Aliment. Pharmacol. Ther. 2014; 39: 1225–1234.
16. Harish K, Nitha R, Harikumar R et al. Prospective evaluation of abnormal liver function tests in pregnancy. Trop. Gastroenterol. 2005; 26: 188–193.
17. Ch'ng CL, Morgan M, Hainsworth I et al. Prospective study of liver dysfunction in pregnancy in Southwest Wales. Gut 2002; 51: 876–880.
18. Yang YB, Li XM, Shi ZJ et al. Pregnant woman with fulminant hepatic failure caused by hepatitis B virus infection: a case report. World J. Gastroenterol. 2004; 10: 2305–2306.
19. Mahtab MA, Rahman S, Khan M et al. Etiology of fulminant hepatic failure: experience from a tertiary hospital in Bangladesh. Hepatobiliary Pancreat. Dis. Int. 2008; 7: 161–164.
20. Hung JH, Chu CJ, Sung PL et al. Lamivudine therapy in the treatment of chronic hepatitis B with acute exacerbation during pregnancy. J. Chin. Med. Assoc. 2008; 71: 155–1558.
21. Pan CQ, Han GR, Jiang HX et al. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin. Gastroenterol. Hepatol. 2012; 10: 520–526.
22. Lu JF, Zhang SB, Liu YL et al. Effect of Peg-interferon-2a combined with adefovir in HBV postpartum women with normal levels of ALT and high levels of HBV DNA. Liver Int. 2015; 35: 1692–16929.
23. A national survey on growth of children under 7 years of age in nine cities of China, 2005. Zhonghua Er Ke Za Zhi 2007; 45: 609–614.
24. Soderstrom A, Norkrans G, Lindh M. Hepatitis B virus DNA during pregnancy and post partum: aspects on vertical transmission. Scand. J. Infect. Dis. 2003; 35: 814–819.
25. ter Borg MJ, Leemans WF, de Man RA et al. Exacerbation of chronic hepatitis B infection after delivery. J. Viral Hepat. 2008; 15: 37–41.
26. Honkoop P, de Man RA, Niesters HG et al. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000; 32: 635–639.
27. Jin YJ, Kim KM, Yoo DJ et al. Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patients. Virol. J. 2012; 9: 239.
28. Lai CL, Gane E, Liaw YF et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 2007; 357: 2576–2588.
29. Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology 2010; 51: 435–444.